Your browser doesn't support javascript.
Impact of preemptive hospitalization on health outcomes at the temporary COVID-19 hospital in Mexico City: a prospective observational study.
Vazquez, Rafael Ricardo Valdez; Gallardo-Rincón, Héctor; Lomelín-Gascon, Julieta; Ville Benavides, Rodrigo; Juárez, Linda Morales; Bello, Héctor Herrera; Castañeda, Lidia Moreno; Chavarria, Adrian Palacios; Castillo, Pablo Escalera; Gonzalez, Luis Esteban Ramirez; Avendaño, Mónica Arboleya; Berlanga, Santiago Treviño; Loza, Reyna Albertina Rosas; Wyssmann, Renate Victoria Álvarez; Lezama, Erika Salinas; Romero, Alonso Gutiérrez; Ortega, María Dolores Niembro; Acosta, Liudmila Villegas; Schotman, Ailyn Cendejas; Montoya, Jennifer Bertin; Rodriguez, Andrea Gonzalez; Ramos, Laura María Badel; Martinez-Juarez, Luis Alberto; Saucedo-Martínez, Rodrigo; Montoya, Alejandra; Tapia-Conyer, Roberto.
  • Vazquez RRV; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Gallardo-Rincón H; Mexico Carlos Slim Foundation, Lago Zurich 245, Presa Falcon Building (Floor 20), Miguel Hidalgo, Mexico City 11529, Mexico.
  • Lomelín-Gascon J; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Ville Benavides R; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Juárez LM; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Bello HH; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Castañeda LM; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Chavarria AP; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Castillo PE; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Gonzalez LER; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Avendaño MA; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Berlanga ST; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Loza RAR; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Wyssmann RVÁ; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Lezama ES; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Romero AG; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Ortega MDN; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Acosta LV; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Schotman AC; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Montoya JB; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Rodriguez AG; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Ramos LMB; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico.
  • Martinez-Juarez LA; Carlos Slim Foundation, Miguel Hidalgo, Mexico City, Mexico.
  • Saucedo-Martínez R; Carlos Slim Foundation, Miguel Hidalgo, Mexico City, Mexico.
  • Montoya A; Carlos Slim Foundation, Miguel Hidalgo, Mexico City, Mexico.
  • Tapia-Conyer R; Carlos Slim Foundation, Miguel Hidalgo, Mexico City, Mexico.
Ther Adv Infect Dis ; 8: 20499361211040325, 2021.
Article in English | MEDLINE | ID: covidwho-1379752
ABSTRACT

INTRODUCTION:

In response to the evolution of the coronavirus disease 2019 (COVID-19) pandemic, the admission protocol for the temporary COVID-19 hospital in Mexico City has been updated to hospitalize patients preemptively with an oxygen saturation (SpO2) of >90%.

METHODS:

This prospective, observational, single-center study compared the progression and outcomes of patients who were preemptively hospitalized versus those who were hospitalized based on an SpO2 ⩽90%. We recorded patient demographics, clinical characteristics, COVID-19 symptoms, and oxygen requirement at admission. We calculated the risk of disease progression and the benefit of preemptive hospitalization, stratified by CALL Score age, lymphocyte count, and lactate dehydrogenase (<8 and ⩾8) at admission.

RESULTS:

Preemptive hospitalization significantly reduced the requirement for oxygen therapy (odds ratio 0.45, 95% confidence interval 0.31-0.66), admission to the intensive care unit (ICU) (0.37, 0.23-0.60), requirement for invasive mechanical ventilation (IMV) (0.40, 0.25-0.64), and mortality (0.22, 0.10-0.50). Stratification by CALL score at admission showed that the benefit of preemptive hospitalization remained significant for patients requiring oxygen therapy (0.51, 0.31-0.83), admission to the ICU (0.48, 0.27-0.86), and IMV (0.51, 0.28-0.92). Mortality risk remained significantly reduced (0.19, 0.07-0.48).

CONCLUSION:

Preemptive hospitalization reduced the rate of disease progression and may be beneficial for improving COVID-19 patient outcomes.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Country/Region as subject: Mexico Language: English Journal: Ther Adv Infect Dis Year: 2021 Document Type: Article Affiliation country: 20499361211040325

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Country/Region as subject: Mexico Language: English Journal: Ther Adv Infect Dis Year: 2021 Document Type: Article Affiliation country: 20499361211040325